Non-Invasive Prenatal Testing Market is expected to grow at a CAGR of 18% during the forecast period 2022-2029. As per Priority Exploration, the worldwide red biotechnology market size is anticipated to hit around US$ 510 billion by 2027 from an estimated at US$ 322 billion out of 2022. The North America region has the highest market share in the Non-Invasive Prenatal Testing Market, and it is further continuing its dominance during the forecast period.
Our research report gives wide perceptions of the latest trends and development prospects of the market analysis, detailed segmentation analysis, volume, size, share, growth drives, and opportunities in the market. In-depth regional and country-level illustration of the competitive landscape depends on several phases and status of clinical trials over the prominent economies of the globe, and also the report contains a number of major companies profiled in the relevant market.
To Download free sample @ Click Here
Absence of openness of harmless pre-birth test and impediment of tests are supposed to hamper the market development
In arising nations, the openness of harmless pre-birth tests is extremely less. In spite of the possible advantages of NIPT, there are a few critical constraints. Misleading positive and bogus negative experimental outcomes do happen, and they might happen at a higher rate in clinical practice than detailed in painstakingly controlled, little clinical preliminaries. The rise of NIPT raises various moral worries for specialists, patients, and society in general. It has been financially promoted, with professionals worried that neglecting to suggest the test might be seen as poor consideration, presenting them to medico-legitimate or reputational risk.
The NIPT is a screening test that can create bogus up-sides and negatives. While testing for illnesses with low dreariness, positive prescient qualities, while high in exactness, are not extremely high. Moreover, the exactness of NIPT in recognizing hereditary problems, barring trisomy 21, 18, and 13, has not been adequately approved; hence, assuming it is to be utilized in clinical practice, it should be made sense of to and completely comprehended by patients.
Instruments & Consumables
Extract reaction plate
Down syndrome (trisomy 21)
Edwards syndrome (trisomy 18)
Patau syndrome (trisomy 13)
Major Companies Covered:
BGI, CENTOGENE AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd (Roche Sequencing), Invitae Corporation, Illumina, Inc., Natera, Inc., Progenity, Inc., PerkinElmer Inc., Quest Diagnostics.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States